Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon TLR7/8 Agonist alone or with pembrolizumab in advanced or metastatic solid tumors
NL-OMON59022Phase 2Completed
- Sponsor
- Ascendis Pharma
- Start
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ACP-017 and pembrolizumab in Non-hematologic malignancy, head and neck squamous cell carcinoma (HNSCC), human papillomavirus-associated cancer and 7 more (6 arms), sponsored by Ascendis Pharma. Primary endpoints: Incidence and severity of serious adverse events and adverse events, Incidence of dose-limiting toxicities and 1 more. Started Jan 2024; status: completed.
02
Drugs
ACP-017pembrolizumab
03
Conditions
Non-hematologic malignancyhead and neck squamous cell carcinoma (HNSCC)human papillomavirus-associated cancermelanomacutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NL-OMON59022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59022.